Agilum Releases RWD Inpatient Mortality Rate Analytics by Age and Gender
The RWD contained herein seeks to provide basic evidence as to role patient age and gender play in predicting mortality from a hospital admission due to COVID-19.
Entries by Rob Coleman
Agilum Releases Additional RWD Survival Rate Analytics for HCQ or CQ and Acetazolamide
Through its Comparative Rapid Cycle Analytics™ (CRCA™) solution, Agilum Healthcare Intelligence seeks to leverage its comprehensive, longitudinal patient database to deliver updates on current and new treatment regimens.
Agilum Releases New York State COVID-19 Drug Utilization Trends Using Real-World Data (RWD) to Help Hospitals Predict Shifting Drug Demand
In response to the rapidly evolving COVID-19 pandemic, Agilum Healthcare Intelligence analyzed real-world data (RWD) from over 29% of the hospital beds in New York state to provide hospitals and pharmacists the evidence-based data to support their ability to predict the growing demand of certain drug inventory for the treatment and supportive care for COVID-19.
Agilum Releases Nationwide COVID-19 Real-World Data (RWD) Survival Rate Analytics
Through its Comparative Rapid Cycle Analytics™ (CRCA™) solution, Agilum Healthcare Intelligence seeks to leverage its comprehensive, longitudinal patient database to deliver updates on current and new treatment regimens.
A new kind of healthcare intelligence with Agilum’s financial analytics team
The Agilum Healthcare Intelligence team is a fundamental component of Agilum’s commitment to unveiling your critical insights. Comprised of a multidisciplinary group of experienced healthcare business analysts and data experts, this team supports and augments an organization’s existing resources by analyzing their clinical, operational, financial and supply chain data to help manage profitability, boost departmental efficiency and optimize revenues. Recently, we sat down with Brian Wedderspoon, VP of Analytics Services, to learn more about what to expect with Agilum’s financial analytics solutions.
Know your numbers: A financial analytics maturity model
Finance leaders at health systems need to keep a sharp eye on the bottom line, yet many struggle to reliably calculate key performance measures.
Agilum has developed a financial analytics maturity model that empowers healthcare organizations to leverage data to manage teams and drive performance improvements across the board. It serves as a roadmap for finance leaders to understand how their performance is aligning to their goals and then pivot as necessary to achieve them.
Data as currency — the value of longitudinal data for pharma
In December 2018, FDA Commissioner Scott Gottlieb, MD, issued a statement about how real-world data (RWD) and real-world evidence (RWE) offer opportunities to understand clinical outcomes of pharmaceutical products.
An incomplete story: What’s missing in longitudinal patient data?
In today’s technology-fueled healthcare industry, data is everywhere. If analyzed properly and used strategically, de-identified, longitudinal patient data can be the key to making good business decisions for hospitals and health systems, payers and pharma manufacturers alike.
Agilum — the road to actionable analytics in healthcare
The genesis of Agilum was to create a data company that could radically change healthcare through the receipt, use, amalgamation, and aggregation of data by enabling hospitals to link this information to patient episodes of care—and in particular, to the administration of drugs.
A broken system — making drug decisions without real-world data
The spiraling cost of prescription drugs is creating unprecedented access and affordability challenges across our healthcare system. From hospital leaders to providers to patients to government, drug prices are on everyone’s radar. And with good cause: According to a January 2019 report from the American Hospital Association, total hospital and health system drug spend increased by 18.5 percent between 2015 and 2017.